Kawasaki Disease

  1. Overview
  2. Diagnostic Criteria
  3. Incomplete Kawasaki Disease
  4. Coronary Artery Aneurysms
  5. Treatment
  6. Echocardiographic Monitoring
  7. Complications
  8. Long-Term Outcomes
  9. Key Research Papers
  10. Connections

Overview

Kawasaki disease (KD) is a self-limited, acute systemic vasculitis that predominantly affects children under 5 years of age. It is the leading cause of acquired heart disease in children in developed countries, having largely displaced acute rheumatic fever in that role over the past several decades. The condition was first described in Japan in 1967 by pediatrician Tomisaku Kawasaki, who reported 50 children with a distinctive fever-plus-rash-plus-lymphadenopathy illness he called "acute febrile mucocutaneous lymph node syndrome."

KD is classified as a medium-vessel vasculitis. Inflammation targets the walls of medium-caliber arteries throughout the body, but the coronary arteries are the vessels most vulnerable to lasting damage. Unchecked inflammation can cause the coronary arterial wall to weaken and balloon outward, forming coronary artery aneurysms (CAA) — the complication that defines long-term prognosis.

The disease peaks between 6 months and 5 years of age, with a typical patient being a 3-year-old male. Boys are affected roughly 1.5 times more often than girls. Incidence is highest in East Asian children (Japan, Korea, Taiwan), where rates of 200–300 per 100,000 children under 5 years are reported annually. In the United States, incidence is approximately 19–25 per 100,000 children under 5 years, translating to roughly 5,000–6,000 hospitalizations per year. Children of Asian or Pacific Islander descent in the US have substantially higher rates than other ethnic groups.

The underlying cause of KD remains unknown despite more than five decades of research. Leading hypotheses involve an abnormal immune response to one or more ubiquitous infectious triggers (viral or bacterial) in genetically susceptible individuals. No single pathogen has been confirmed. Seasonal clustering (winter-spring peaks) and epidemic waves support an infectious or environmental exposure trigger, but person-to-person transmission has not been demonstrated.

Back to Table of Contents

Diagnostic Criteria

Kawasaki disease is a clinical diagnosis — no single laboratory test or imaging finding is pathognomonic. The American Heart Association (AHA) criteria require fever lasting 5 or more days plus at least 4 of the following 5 principal features:

  1. Bilateral non-purulent (non-exudative) conjunctival injection — redness of the bulbar conjunctivae without discharge; begins within days of fever onset; limbic sparing (a pale ring around the iris) is characteristic.
  2. Polymorphous rash — appears on the trunk and extremities within the first 5 days; most commonly a maculopapular or morbilliform eruption; may be urticarial, erythema multiforme-like, or scarlatiniform; vesicular or bullous lesions are not consistent with KD.
  3. Oropharyngeal changes — includes any combination of: strawberry tongue (erythema and prominence of fungiform papillae), lip erythema and cracking/fissuring, and diffuse oropharyngeal erythema. Ulceration, vesicles, and exudate are atypical.
  4. Changes of the extremities — acute phase: erythema and/or induration (firm swelling) of the palms and soles; subacute/convalescent phase (weeks 2–3): periungual desquamation beginning at the fingertips and spreading proximally. This peeling is essentially pathognomonic when present.
  5. Cervical lymphadenopathy — at least one lymph node measuring >1.5 cm in diameter; typically unilateral, involves a single anterior cervical node, and is often firm and minimally tender.

A child with fever for 5 or more days plus all 5 features can be diagnosed with classic (complete) KD. In the AHA guidelines, a patient with 4 days of fever can be diagnosed if 4 or more criteria are present and an experienced clinician considers the diagnosis consistent. Fever is typically high (39–40 °C), remittent, and unresponsive to antipyretics and antibiotics — a pattern that itself is a clinical clue.

The fever and most mucocutaneous features resolve within 2–4 weeks without treatment. However, coronary artery inflammation begins early in the course and may progress despite apparent clinical improvement, making early diagnosis and treatment critical.

Back to Table of Contents

Incomplete Kawasaki Disease

Incomplete (atypical) Kawasaki disease refers to children who have fever for 5 or more days and only 2 or 3 of the 5 principal features, yet develop coronary artery abnormalities (CAA) consistent with KD. The term "incomplete" is preferred over "atypical" because the missing features likely reflect the same disease process at an earlier or milder stage, not a different disease.

Incomplete KD is particularly dangerous because it is more likely to be missed. Infants younger than 12 months are at highest risk: they frequently present with fever alone or with very few classic features, yet have the highest rates of CAA — up to 25% in some series — if untreated. Any infant under 6 months with unexplained fever lasting 7 or more days warrants echocardiography even without other KD features.

The AHA/American Academy of Pediatrics (AAP) diagnostic algorithm for incomplete KD uses laboratory and echocardiographic criteria when clinical features are insufficient:

Per the AHA algorithm, if CRP and ESR are elevated in a child with prolonged fever and 2–3 features, supplemental labs are checked. If 3 or more supplemental criteria are met, treatment should be initiated. If supplemental labs are equivocal but clinical suspicion remains high, echocardiography is performed — and treatment given if echo is abnormal. A normal echo in the first week does not exclude the diagnosis; repeat imaging at 2 weeks is essential.

Back to Table of Contents

Coronary Artery Aneurysms

The defining complication of Kawasaki disease is damage to the coronary arteries. Without treatment, approximately 25% of children develop coronary artery aneurysms (CAA). With standard IVIG therapy given within the first 10 days of fever, this rate drops to approximately 4%.

Aneurysms are classified by the internal luminal diameter or, in children, by the coronary Z-score (number of standard deviations above the mean for body surface area):

The proximal left anterior descending (LAD) and right coronary artery (RCA) are most frequently involved. The left main coronary artery (LMCA) is also affected in some cases. Aneurysms are rarely solitary — when present, multiple segments are typically involved.

Small and medium aneurysms often regress on follow-up echocardiography over months to years as the inflammatory process resolves, but regression does not necessarily indicate restoration of normal arterial wall structure. The internal elastic lamina may be permanently disrupted, predisposing to accelerated atherosclerosis, stenosis, and thrombosis decades later.

Giant aneurysms carry the highest risk. Turbulent flow within the dilated segment promotes thrombosis, which can cause acute myocardial infarction — even in toddlers. Children with giant aneurysms require aggressive long-term anticoagulation and cardiology surveillance throughout life. Stenosis developing at the inlet and outlet of a regressing aneurysm is a well-recognized late complication that may precipitate ischemia without obvious thrombosis.

Back to Table of Contents

Treatment

The cornerstone of KD treatment is intravenous immunoglobulin (IVIG) combined with aspirin, ideally initiated within the first 10 days of fever onset — and as early as possible once the diagnosis is established.

Primary Treatment

IVIG Resistance

Approximately 10–20% of children do not defervesce within 36 hours after the initial IVIG infusion — a phenomenon called IVIG resistance. These children are at higher risk for CAA and require additional therapy:

Risk Prediction Scores

Three Japanese scoring systems predict IVIG resistance before treatment is given, allowing risk stratification:

These scores perform better in Japanese populations than in Western cohorts and should not be used as the sole basis for treatment decisions outside Japan, but they provide useful prognostic context.

Back to Table of Contents

Echocardiographic Monitoring

Echocardiography is essential at three standard time points in every child diagnosed with KD:

  1. At diagnosis (or as soon as possible after) — establishes a baseline and may reveal early coronary changes or pericardial effusion.
  2. At 2 weeks — peak period for coronary aneurysm formation; the most critical follow-up study.
  3. At 6–8 weeks — documents resolution or persistence of coronary abnormalities; guides decision on continuing aspirin and scheduling further surveillance.

All coronary artery measurements should be expressed as Z-scores normalized for body surface area, not absolute diameter alone, because coronary artery dimensions scale with body size. The proximal segments of the LAD and RCA are most susceptible to aneurysm formation and must be measured at every study. The LMCA, proximal circumflex, and posterior descending artery are also evaluated.

If the initial and 2-week echocardiograms are normal and the child had classic KD with good clinical response to IVIG, no further echocardiographic follow-up is typically required beyond the 6–8 week study. If coronary abnormalities are detected, the frequency and duration of surveillance depend on the risk tier defined in the 2017 AHA guidelines:

Back to Table of Contents

Complications

While coronary artery aneurysms are the most feared complication, KD produces systemic vasculitis that can affect multiple organ systems:

Back to Table of Contents

Long-Term Outcomes

The great majority of children who receive timely treatment with IVIG recover completely with no lasting cardiac sequelae. Fever resolves, inflammatory markers normalize, and mucocutaneous features fade over 2–4 weeks. For children who never develop coronary abnormalities, long-term prognosis is essentially normal.

However, for the minority with persistent or giant aneurysms, KD becomes a lifelong cardiovascular disease. Giant aneurysms do not fully regress and carry compounding risks over decades:

Adults who had KD in childhood — many of whom were never diagnosed — may present with premature coronary artery disease, MI, or sudden cardiac death. This has led to retrospective recognition of KD as a cause of "unexplained" MI in young adults, particularly those of Asian descent.

Multisystem Inflammatory Syndrome in Children (MIS-C), identified during the COVID-19 pandemic, shares several features with KD — prolonged fever, conjunctivitis, rash, mucocutaneous changes, and coronary artery dilation — and has been called a "Kawasaki-like" illness. MIS-C typically affects older children (median age 8–9 years), more often causes gastrointestinal symptoms, shock, and myocarditis, and follows SARS-CoV-2 infection by 2–6 weeks. The two conditions are clinically distinct but may share immunopathogenic mechanisms (PMID 32360583).

Long-term management for high-risk KD patients includes aspirin (and anticoagulation for giant aneurysms), exercise restriction proportional to aneurysm size, periodic stress testing and coronary CT or MR angiography, and statin therapy in some guidelines. Percutaneous coronary intervention and bypass grafting are occasionally required for stenotic lesions.

Back to Table of Contents

Key Research Papers

  1. Kawasaki T, 1967 — Acute febrile mucocutaneous lymph node syndrome: clinical observations of 50 cases — PMID: 3624180
  2. Newburger JW et al., 2004 — AHA Scientific Statement on Kawasaki Disease (Circulation) — PMID: 15281380
  3. Kobayashi T et al., 2006 — Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease: the Kobayashi score (Pediatrics) — PMID: 16950983
  4. McCrindle BW et al., 2017 — AHA Scientific Statement: Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease (Circulation) — PMID: 27002586
  5. Newburger JW et al., 1991 — A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome (N Engl J Med) — PMID: 1574194
  6. Tremoulet AH et al., 2014 — Infliximab for intensification of primary therapy for Kawasaki disease (Lancet) — PMID: 23275434
  7. Son MB, Newburger JW, 2013 — Kawasaki disease (Pediatr Rev) — PMID: 25446706
  8. Friedman KG et al., 2018 — Coronary artery aneurysm outcomes in Kawasaki disease (JAMA Pediatr) — PMID: 30455421
  9. Egami K et al., 2006 — Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease: the Egami score (J Pediatr) — PMID: 16720205
  10. Sano T et al., 2007 — A new prediction scoring system for the risk of non-responsive Kawasaki disease: the Sano score (J Pediatr) — PMID: 17719063
  11. Shulman ST, Rowley AH, 2018 — Kawasaki disease: insights into pathogenesis and approaches to treatment (Nat Rev Rheumatol) — PMID: 29330252
  12. Verdoni L et al., 2020 — An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic (Lancet) — PMID: 32360583

PubMed Topic Searches

  1. Kawasaki disease coronary artery aneurysm
  2. Kawasaki disease IVIG treatment
  3. Incomplete Kawasaki disease diagnosis
  4. Kawasaki disease IVIG resistance infliximab
  5. MIS-C Kawasaki-like COVID-19

Back to Table of Contents

Connections

Back to Table of Contents